Mass spectrometry imaging (MSI) is a proven and effective tool for evaluating the in situ distribution of proteins, peptides, lipids, or metabolites within biological specimens.1,2
MSI acquires molecular data that provide insights into the biochemical variations within clinical specimens. These biochemical variations can be correlated with specific histological features and disease states. Hundreds of biomolecules can be monitored simultaneously to obtain a comprehensive molecular profile of clinical specimens. Through the use of bioinformatics tools, these molecular profiles can be statistically assessed to differentiate between healthy and diseased tissue types, to differentiate between diseases with similar clinical presentations, and to identify molecular distinctions linked to treatment response. This ability to differentiate between phenotypes, in contrast to gene-based profiling tests, enables the development of more accurate diagnostic and prognostic tests.